Verano Holdings (VRNO) Other Non-Current Liabilities (2022 - 2026)
Verano Holdings (VRNO) posted quarterly Other Non-Current Liabilities of $1.5 million for Q1 2026, down 37.99% year-over-year from $2.5 million in Q1 2025, and up 42.37% quarter-over-quarter from $1.1 million in Q4 2025.
Verano Holdings (VRNO) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Other Non-Current Liabilities for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 37.99% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 37.99% YoY), while the FY2025 annual figure was $1.1 million, down 43.43% from the prior year.
- Other Non-Current Liabilities grew to $1.5 million in Q1 2026 per VRNO's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $66.9 million in Q2 2022 and bottomed at $255000.0 in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $10.3 million across 5 years, with a median of $3.5 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities tumbled 95.75% — and 2024, when it jumped 649.41%.
- Verano Holdings' Other Non-Current Liabilities stood at $6.0 million in 2022, then sank by 95.75% to $255000.0 in 2023, then surged by 649.41% to $1.9 million in 2024, then sank by 43.43% to $1.1 million in 2025, then jumped by 42.37% to $1.5 million in 2026.
- Business Quant data shows VRNO's Other Non-Current Liabilities at $1.5 million in Q1 2026, $1.1 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Verano Holdings | 438.82 Mn | 353.62 Mn | 99.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 444,000.00 |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 3.78 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 255,000.00 |
| Sep 30, 2023 | 4.95 Mn |
| Jun 30, 2023 | 4.95 Mn |
| Mar 31, 2023 | 5.74 Mn |
| Dec 31, 2022 | 5.99 Mn |
| Sep 30, 2022 | 53.74 Mn |
| Jun 30, 2022 | 66.90 Mn |